IR/PR

SK Plasma has entered into a licensing and joint development agreement with AimedBio to in-license AMB303, a late-stage preclinical antibody-drug conjugate (ADC) targeting ROR1. The agreement grants SK Plasma exclusive rights for development and commercialization, with the two companies set to collaborate from preclinical through clinical and commercial stages. IND submissions in both Korea and the U.S. are planned for 2026.
 
AMB303 was developed using AimedBio’s proprietary platforms for target discovery, antibody generation, and linker-payload engineering. It is one of the company’s advanced ADC candidates, designed to selectively target solid tumors expressing ROR1.
 
AimedBio, founded in 2018 as a spin-off from Samsung Medical Center, is led by Dr. Do-Hyun Nam, a globally recognized leader in neuro-oncology. The company has a proven track record in ADC innovation, having recently licensed another program to U.S.-based Biohaven.
 
“We’re pleased to partner with SK Plasma, whose clinical and commercial capabilities make them an ideal collaborator for advancing AMB303 globally,” said Dr. Nam-Gu Her, CEO of AimedBio. “This agreement reflects growing global recognition of AimedBio’s ADC pipeline and platform.”
 
The financial terms of the deal remain undisclosed. For SK Plasma, this marks a strategic entry into the ADC field as part of its broader push into biologics and treatments for rare and intractable diseases.

Link to full news: https://www.skchemicals.com/en/prcenter/new_view.aspx?serno=3676